OPKO has acquired exclusive worldwide rights from The Scripps Research Institute to leading preclinical candidate SR-3306 and related small molecule compounds.
These compounds can inhibit a class of enzymes called jun-N-terminal kinases (JNK), which play an important role in neuron survival.
Research indicates that compound SR-3306 could act as a neuroprotective defense against Parkinson’s disease. To date, research on SR-3306 has been conducted in the laboratory of Dr. Philip LoGrasso at Scripps.
SR-3306 has demonstrated:
- Oral bioavailability and CNS penetration in animal models
- Efficacy in 2 animal models of Parkinson’s disease
- Potential relevance to other neurodegenerative disease treatments, including Alzheimer’s disease, multiple sclerosis, ALS, and stroke
- Potential first-in-class neuroprotection via inhibition of JNK